Latest studies
- RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Singapore - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positiveSingapore - RecruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaSingapore - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
Endometrial CancerSingapore - RecruitingPHASE2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study looks at whether a new medicine, BI 764198, can help adults and teenagers with certain kidney problems. It compares the new medicine to a dummy pill to see if it reduces protein in the urine and improves kidney health.
Proteinuric Kidney DiseasesSingapore - Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
This study looks at issues that can happen when breathing tubes are removed after surgery or critical illness. Researchers want to understand why these problems happen and how medical teams can improve this common procedure to make it safer for everyone.
ExtubationSingapore - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
This study compares a new medicine, empasiprubart, with standard IVIg treatment for adults with CIDP. It looks at how well they work and if they are safe. Participants will receive one of these treatments, or a dummy treatment, for several months.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathySingapore - RecruitingPHASE2
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This study is looking into a new medicine called zongertinib for people with advanced cancers. It focuses on cancers where HER2, a protein, has changed. The goal is to see if zongertinib can help by blocking these changes in HER2.
Solid TumoursSingapore - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
Breast NeoplasmsSingapore - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Singapore - RecruitingPHASE3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
This study looks at a new medicine called muvalaplin to see if it can lower the risk of heart attacks and strokes in people with high levels of a specific fat in their blood called Lp(a).
Elevated Lp(a)Atherosclerotic Cardiovascular Disease (ASCVD)Singapore - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast NeoplasmsSingapore - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisSingapore - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)Singapore - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerSingapore - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorSingapore - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Singapore - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
Breast CancerSingapore - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
Colon AdenocarcinomaRectal AdenocarcinomaSingapore - RecruitingPHASE1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
This study is looking into a new medicine, LOXO-783, for breast cancer and other solid tumours with a specific gene change (PIK3CA). It aims to understand if the medicine is safe, what side effects it has, and how well it works.
Breast CancerSingapore - RecruitingPHASE3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This study is testing a new drug, camizestrant, for early breast cancer that's hormone-sensitive. We want to see if it works better than standard hormone therapy in reducing the risk of cancer coming back, for people who have already had initial treatment.
Breast Cancer, Early Breast CancerSingapore - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
Endometrial CancerSingapore - RecruitingPHASE2
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
This study looks at giving a second course of ianalumab to adults with certain blood conditions (ITP or wAIHA) if their first treatment worked but then stopped or wasn't enough. It's to see if a second round is safe and helps them again.
Primary Immune ThrombocytopeniaWarm Autoimmune Hemolytic AnemiaSingapore - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
Prostate CancerProstatic NeoplasmsSingapore - RecruitingPHASE3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
This study is looking into a new medicine called Seladelpar for people with a liver condition called Primary Biliary Cholangitis (PBC) and mild liver scarring (cirrhosis). It aims to see how well Seladelpar works compared to a dummy pill to improve health outcomes.
Primary Biliary CholangitisSingapore - Active not recruitingPHASE2
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
This study looks at a new treatment called patritumab deruxtecan for people with an advanced type of lung cancer that has a specific genetic change (EGFR mutation). It's for those who have already tried other standard treatments that are no longer working.
Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorSingapore - Recruiting
Pancreatic Cancer Early Detection Consortium
This study aims to find better ways to spot pancreatic cancer early, especially in people with a higher risk due to family history or specific genetic changes. Researchers will collect health information and samples over time to understand how the disease develops.
Pancreas CancerPancreas CystPancreatic Ductal AdenocarcinomaGenetic PredispositionSingapore - Recruiting
An International Observational Study of Adults With Acute Infection
This study looks at adults admitted to hospital with infections. Researchers will collect information and samples to better understand different types of infections, how they affect people, and how best to treat them. This helps plan future studies and improve care.
Infectious DiseaseSingapore - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaSingapore - RecruitingPHASE2
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
This study is testing a new medicine, MK-5684, for breast, ovarian, and endometrial cancers. It aims to see if MK-5684, which blocks steroid hormones, can stop cancer from growing or spreading for longer than current standard treatments.
Malignant NeoplasmSingapore - Active not recruitingPHASE1, PHASE2
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
This study is testing a new combination treatment for a type of lung cancer called Extensive Stage Small Cell Lung Cancer (ES-SCLC). It aims to find a safe dose and see if this new combination works better than current treatments for people newly diagnosed with this aggressive cancer.
Extensive Stage Small Cell Lung CancerSingapore - Active not recruitingPHASE3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
This study compares two treatments, XL092 (plus atezolizumab) and regorafenib, for advanced bowel cancer that has spread. It's for people whose cancer hasn't responded well to previous common treatments. We want to see which treatment works better to control the cancer.
Colorectal CancerSingapore - Active not recruitingPHASE2
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
This study is testing a new medicine called tarlatamab for people with a type of lung cancer called Small Cell Lung Cancer (SCLC) that has come back or not responded to previous treatments. It aims to see how safe and effective the new medicine is.
Relapsed/Refractory Small Cell Lung CancerSingapore - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)Singapore - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
Prostatic NeoplasmsSingapore - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)Singapore - Enrolling by invitationPHASE2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
This study looks at a medicine called Infigratinib for children and teenagers aged 3-18 with achondroplasia, a type of dwarfism. It's an ongoing study to check the medicine's safety, how well it works, and its long-term effects on growth and quality of life.
AchondroplasiaSingapore - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
Papillary Renal Cell CarcinomaSingapore - RecruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal AdenocarcinomaSingapore - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
Metastatic Prostate CancerProstate AdenocarcinomaSingapore - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisSingapore - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsSingapore - Enrolling by invitationPHASE3
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
This study looks at the long-term effects and safety of a drug called Ralinepag for people with a lung condition called pulmonary arterial hypertension (PAH). It's for those who have already tried Ralinepag in a previous study.
PAHPulmonary HypertensionPulmonary Arterial HypertensionHypertensionSingapore - Active not recruitingPHASE2
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is looking at a new treatment called tislelizumab, sometimes combined with other medicines, for head and neck cancer that has come back or spread. The aim is to see if it can shrink tumours and if it's safe for patients.
Head and Neck Squamous Cell CarcinomaHead and Neck CancerSingapore - Active not recruitingPHASE3
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
This study looks at the long-term safety and effectiveness of a new medicine, ianalumab, for people with Sjögren's Syndrome. It's for those who have already completed an earlier study and aims to see how well the treatment works and if it has any long-term side effects.
Sjogrens SyndromeSingapore - Active not recruitingPHASE3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This study looks at new drug combinations for advanced breast cancer that has grown despite previous treatments. It compares different medications, including gedatolisib, fulvestrant, and palbociclib, to see if they are safe and effective.
Breast CancerSingapore - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaSingapore - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesSingapore - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseSingapore - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticSingapore